Peptide Synthesis Market Analysis

Application Segment Analysis

The pharmaceuticals (therapeutics) segment, which is part of the application, is anticipated to hold the largest share of 68.5% in the peptide synthesis market by the end of 2035. The segment’s upliftment is highly attributed to its dependence on peptide synthesis to develop highly potent and specific drugs, such as GLP-1 agonists for antimicrobials and diabetes, constituting tailored properties that tend to mimic natural body functions. According to an article published by NLM in November 2023, domestic manufacturers usually contribute 80% of pharmaceutical units purchased in countries, out of which only 33% of the value, and the average price of imported medicines is 8 times higher than produced medicines. Besides, in terms of research and development funding, USD 240 billion has been spent in total, of which 89%, that is USD 214 billion, has been invested across high-income countries, and 11%, that is USD 26 billion, caters to low and middle-income nations, thereby deliberately fueling the segment’s growth.

Technology Segment Analysis

The solid-phase peptide synthesis (Fmoc) segment in the peptide synthesis market is expected to account for the second-largest share during the forecast timeline. The segment’s growth is highly driven by the aspect of providing high efficiency, scalability, and compatibility with automation, making it the preferred method for both research and commercial peptide production. This particular technique involves sequential addition of amino acids to a growing peptide chain anchored to a resin, with the Fmoc group serving as a temporary protective group that can be removed under mild conditions. This reduces side reactions and enhances purity compared to Boc chemistry. Fmoc-SPPS is particularly advantageous for synthesizing long and complex peptides, including therapeutic APIs, due to its ability to achieve high yields with minimal degradation.

Scale of Operation Segment Analysis

By the end of the stipulated timeline, the commercial segment is projected to garner the third-largest share in the peptide synthesis market. The segment’s development is effectively fueled by the transition from laboratory-scale research to industrial-scale GMP manufacturing. Commercial peptide synthesis involves producing kilogram-scale batches of APIs and reagents for pharmaceutical companies, biotechnology firms, and CDMOs. This segment is driven by rising demand for peptide-based therapeutics, including GLP-1 analogs for diabetes and obesity, peptide vaccines, and oncology treatments. Commercial operations require advanced infrastructure, automated synthesizers, and stringent quality control systems to meet regulatory standards set by agencies such as the FDA and EMA. Investments in large-scale SPPS facilities, solvent recovery systems, and continuous manufacturing technologies have improved efficiency and reduced costs.

Our in-depth analysis of the peptide synthesis market includes the following segments: